jeudi 7 décembre 2017

Onco Actu du 7 décembre 2017

2.8 Etiologie - Contraceptifs, THS

Newer birth control pills still modestly raise risk of breast cancer [STAT]

Even Low-Dose Contraceptives Slightly Increase Breast Cancer Risk [NPR]

Study confirms higher breast cancer risk with hormone-based contraception [Reuters]

Birth Control Pills Still Linked to Breast Cancer, Study Finds [NY Times]

All forms of hormonal contraception carry breast cancer risk, study finds [The Guardian]

4.13 Dép., diag. & prono. - Peau

Looking Below The Locks: Teaching Hairdressers To Spot Melanoma [NPR]

5. Traitements

An old drug for alcoholism finds new life as cancer treatment [Science]

The OlympiAD trial: who won the gold? [ecancermedicalscience]

5.12 Immunothérapies

There are 2,004 cancer immunotherapies crowding into the pipeline. Now what? [EndPoints]

Landscape of Immuno-Oncology Drug Development [Cancer Research Institute]

5.12.1 Immunothérapies - partenariats

Juno inks deals with Eli Lilly, the Hutch as it looks to leapfrog leaders on BCMA [EndPoints]

5.12.2 Immunothérapies - CAR-T

Biotech veteran Gilman is back, heading up next-gen CAR-T startup Obsidian [FierceBiotech]

Looking for the next big breakthrough in CAR-T, Mike Gilman debuts Obsidian with $49.5M round [EndPoints]

5.2 Pharma

Clovis' Rubraca takes aim at Lynparza, Zejula with priority review for new use [FiercePharma]

5.2.1 Pharma - Partenariats

Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score™ Test for Potential Drug Development [PR Newswire]

5.3 Traitements - FDA, EMA, NICE...

FDA Launches Predictive Toxicology Roadmap to Enable Advances in Toxicity Testing [FDA Voice]

Cancer R&D tips the scales at the FDA as active INDs climb to record high [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA)

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer [NCI]

5.4 Traitements - Economie

NICE issues early 'no' votes on Roche's RoActemra, Novartis' Rydapt [FiercePharma]

Novartis nets first acute myeloid leukaemia approval in Canada, but NICE says no [Pharmafile]

5.6 ESMO

ESMO IO 2017 Press Release: First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer [ESMO]

Looking for a come-from-behind win, Roche touts its pivotal success for Tecentriq combo in front-line lung cancer [EndPoints]

Roche drug cocktail doubles chance of holding lung cancer at bay [Reuters]

Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer [Roche]

5.8 ASH

59th ASH Annual Meeting to Celebrate Major Advances in Hematology Research [ASH]

5.9.1 AACR - sein

Updated Data from Phase 3 Trial of IBRANCE® (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival [Pfizer]

Myriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium [Myriad]

Kisqali® first and only CDK4/6 inhibitor to show superior efficacy vs. oral endocrine therapy as 1L treatment in randomized Phase III trial in premenopausal women with HR+/HER2- advanced breast cancer [Novartis]

Increasing the Dose Intensity of Chemotherapy May Lower the Risk of Breast Cancer Recurrence and Death [AACR]

Immunotherapy Shows Early Promise for Patients With Trastuzumab-resistant Breast Cancer [AACR]

Adjuvant Trastuzumab Did Not Improve Outcomes for Patients With HER2-low Breast Cancer [AACR]

Ribociclib Improved Progression-free Survival for Pre- and Perimenopausal Women With Hormone Receptor–positive Advanced Breast Cancer [AACR]

6.10.1 Politiques (USA)

Ninety-Six Leading Cancer Researchers and Physician-Scientists, Including Eighteen Nobel Laureates, Urge Congress to Reach a Bipartisan Budget Agreement and Invest in Lifesaving Medical Research [AACR]

6.9 Controverses

There’s No Such Thing As ‘Sound Science’ [FiveThirtyEight]